Want to see AVBP full AI Analyst Report?
AVBP Stock Chart & Stats
$31.73
-$0.27(-0.85%)
At close: 4:00 PM EDT
$31.73
-$0.27(-0.85%)
Day’s Range― - ―
52-Week Range$16.10 - $35.83
Previous CloseN/A
Volume264.76K
Average Volume (3M)599.47K
Market Cap
$1.39B
Enterprise Value$713.75
Total Cash (Recent Filing)$326.38M
Total Debt (Recent Filing)$419.00K
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 18, 2026EPS Estimate
-0.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.53
Shares Outstanding46,574,930
10 Day Avg. Volume525,635
30 Day Avg. Volume599,470
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.52
Price to Sales (P/S)0.00
P/FCF Ratio-4.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.08Price Target Upside35.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-4.11
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a materially larger asset base provide durable financial flexibility versus peers. A strengthened balance sheet reduces near-term refinancing pressure, supports continued R&D spending, and buys time for clinical programs to progress before additional external financing is required.
Focused Oncology PipelineA clear strategic focus on targeted oncology and a lead EGFR inhibitor gives the company technical differentiation and concentrated R&D expertise. Over 2–6 months this specialization supports efficient trial design, potential regulatory clarity in defined indications, and durable relevance if clinical readouts advance.
Access To Equity CapitalAn active ATM program institutionalizes the ability to raise sizable equity capital on demand, providing a durable mechanism to fund clinical development and operations. This structural financing flexibility reduces the immediacy of liquidity shocks and supports multi-stage program financing.
Bears Say
Pre-Revenue And Widening LossesSustained pre-revenue status and materially widening net losses indicate the company cannot self-fund growth. Over months this erodes equity value if burn continues, forces dependence on external financing, and constrains reinvestment choices until clinical milestones translate into revenue.
Persistent Cash BurnConsistently negative operating and free cash flows reflect real cash outlays for development; free cash flow tracks net loss closely, so losses are cash-driven. This creates a durable funding requirement: without new capital the company must slow programs or face dilution from frequent financings.
Clinical And Regulatory Binary RiskBeing clinical-stage means outcomes hinge on trial results and regulatory approvals, a structural binary risk. Over 2–6 months, trial readouts or regulatory actions can materially change prospects; high failure rates and long timelines make revenue realization uncertain and sustain financing pressure.
ArriVent BioPharma, Inc. News
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $16.10 and its highest was $35.83 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
ArriVent BioPharma, Inc.’s market cap is $1.39B.
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 11 days.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on May 11, 2026. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.895 by -$0.065.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -0.99.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 46,574,930 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.895. Following the earnings report the stock price went down -0.172%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Currently, no hedge funds are holding shares in AVBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ArriVent BioPharma, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.08 (35.78% Upside)
$43.08 (35.78% Upside)
Blogger Sentiment
Bullish
AVBP Sentiment 100%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 35.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
62.09%
Trailing 12-Months
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
AVBP Stock 12 Month Forecast
Average Price Target
$43.08
▲(35.78% Upside)
Technical Analysis
uniQure
―
Iovance Biotherapeutics
―
Relay Therapeutics
―
Inventiva
―
Taysha Gene Therapies
―
Ownership Overview
9.57% Insiders
12.10% Mutual Funds
0.42% Other Institutional Investors
65.73% Public Companies and
Individual Investors